Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST HER2 substudy of trastuzumab emtansine in advanced HER2-altered tumors
ACTRN12619001265167Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Jun 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab emtansine in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by The University of Sydney. Primary endpoint: Disease control. Started Jun 2020; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12619001265167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001265167.